Inflammatory bowel diseases (IBDs), primarily ulcerative colitis and Crohn's disease, are inflammatory disorders caused by multiple factors. Research on IBD has often used the dextran sodium sulfate (DSS)-induced colitis mouse model. DSS induces in vivo but not in vitro intestinal inflammation. In addition, no DSS-associated molecule (free glucose, sodium sulfate solution, free dextran) induces in vitro or in vivo intestinal inflammation. We find that DSS but not dextran associated molecules established linkages with medium-chain-length fatty acids (MCFAs), such as dodecanoate, that are present in the colonic lumen. DSS complexed to MCFAs forms nanometer-sized vesicles ~200 nm in diameter that can fuse with colonocyte membranes. The arrival of nanometer-sized DSS/MCFA vesicles in the cytoplasm may activate intestinal inflammatory signaling pathways. We also show that the inflammatory activity of DSS is mediated by the dextran moieties. The deleterious effect of DSS is localized principally in the distal colon, therefore it will be important to chemically modify DSS to develop materials beneficial to the colon without affecting colon-targeting specificity.
References
[1]
Orholm M, Munkholm P, Langholz E, Nielsen OH, Sorensen TI, et al. (1991) Familial occurrence of inflammatory bowel disease. N Engl J Med 324: 84–88.
[2]
Lowe AM, Roy PO, M BP, Michel P, Bitton A, et al. (2009) Epidemiology of Crohn's disease in Quebec, Canada. Inflamm Bowel Dis 15: 429–435.
[3]
Brant SR (2011) Update on the heritability of inflammatory bowel disease: the importance of twin studies. Inflamm Bowel Dis 17: 1–5.
[4]
Skewis LR, Reinhard BM (2010) Control of colloid surface chemistry through matrix confinement: facile preparation of stable antibody functionalized silver nanoparticles. ACS applied materials & interfaces 2: 35–40.
[5]
Riva G, Wiederhold BK, Mantovani F, Gaggioli A (2011) Interreality: the experiential use of technology in the treatment of obesity. Clinical practice and epidemiology in mental health : CP & EMH 7: 51–61.
[6]
Schlitt HJ, Mornex F, Shaked A, Trotter JF (2011) Immunosuppression and hepatocellular carcinoma. Liver transplantation: official publication of the American Association for the Study of Liver Diseases and the International Liver Transplantation Society.
[7]
Magitta NF, Pura M, Wolff ASB, Vanuga P, Meager A, et al. (2008) Autoimmune polyendocrine syndrome type I in Slovakia: relevance of screening patients with autoimmune Addison's disease. European journal of endocrinology/European Federation of Endocrine Societies 158: 705–709.
[8]
Hu Y, Mak JF, Lu WW, Cheung KM, Luk KD (2004) Visualization of lumbar muscle contraction synergy using surface electromyography (sEMG) streaming topography. Conference proceedings : Annual International Conference of the IEEE Engineering in Medicine and Biology Society IEEE Engineering in Medicine and Biology Society Conference 3: 2337–2340.
[9]
Walsh DA, McWilliams DF (2006) Tachykinins and the cardiovascular system. Current drug targets 7: 1031–1042.
[10]
Pinho RA, Silveira PC, Silva LA, Luiz Streck E, Dal-Pizzol F, et al. (2005) N-acetylcysteine and deferoxamine reduce pulmonary oxidative stress and inflammation in rats after coal dust exposure. Environmental research 99: 355–360.
[11]
Toth G, R FM, Lovas S (2001) Stabilization of local structures by pi-CH and aromatic-backbone amide interactions involving prolyl and aromatic residues. Protein engineering 14: 543–547.
[12]
Miyazawa F, Olijnyk OR, Tilley CJ, Tamaoki T (1967) Interactions between dextran sulfate and Escherichia coli ribosomes. Biochimica et biophysica acta 145: 96–104.
[13]
Nakamura T, Katori R, Watanabe T, Miyazawa K, Murai M, et al. (1967) Quantitation of left-to-right shunt from a single earpiece dye-dilution curve. Journal of applied physiology 22: 1156–1160.
[14]
Nakamura T, Katori R, Miyazawa K, Oda J, Ishikawa K (1967) Measurement of bronchial blood flow in tetralogy of Fallot. Circulation 35: 904–912.
[15]
Yan Y, Kolachala V, Dalmasso G, Nguyen H, Laroui H, et al. (2009) Temporal and spatial analysis of clinical and molecular parameters in dextran sodium sulfate induced colitis. PLoS One 4: e6073.
[16]
Rogler G, Andus T (1998) Cytokines in inflammatory bowel disease. World J Surg 22: 382–389.
[17]
Kennedy RJ, Hoper M, Deodhar K, Erwin PJ, Kirk SJ, et al. (2000) Interleukin 10-deficient colitis: new similarities to human inflammatory bowel disease. Br J Surg 87: 1346–1351.
[18]
Steidler L, Hans W, Schotte L, Neirynck S, Obermeier F, et al. (2000) Treatment of murine colitis by Lactococcus lactis secreting interleukin-10. Science 289: 1352–1355.
[19]
Hofstetter C, Kleen M, Habler O, Allmeling AM, Krombach F, et al. (1998) Recombinant human interleukin-10 attenuates TNFalpha production by porcine monocytes. Eur J Med Res 3: 299–303.
[20]
Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest 69: 238–249.
[21]
Cooper HS, Murthy SN, Shah RS, Sedergran DJ (1993) Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Laboratory investigation; a journal of technical methods and pathology 69: 238–249.
[22]
Dignass A, Preiss JC, Aust DE, Autschbach F, Ballauff A, et al. (2011) [Updated German Guideline on Diagnosis and Treatment of Ulcerative Colitis, 2011.]. Zeitschrift fur Gastroenterologie 49: 1276–1341.
[23]
Miyazawa F, Olijnyk OR, Tilley CJ, Tamaoki T (1967) Interactions between dextran sulfate and Escherichia coli ribosomes. Biochim Biophys Acta 145: 96–104.
[24]
Fellig J, Wiley CE (1959) The inhibition of pancreatic ribonuclease by anionic polymers. Arch Biochem Biophys 85: 313–316.
[25]
Philipson L, Zetterqvist O (1964) The Presence of DNA in Human Erythrocyte Membranes. Biochim Biophys Acta 91: 171–173.
[26]
Kim IW, Myung SJ, Do MY, Ryu YM, Kim MJ, et al. (2010) Western-style diets induce macrophage infiltration and contribute to colitis-associated carcinogenesis. Journal of gastroenterology and hepatology 25: 1785–1794.
[27]
Coyne CB, Kelly MM, Boucher RC, Johnson LG (2000) Enhanced epithelial gene transfer by modulation of tight junctions with sodium caprate. American journal of respiratory cell and molecular biology 23: 602–609.
[28]
Lindmark T, Nikkila T, Artursson P (1995) Mechanisms of absorption enhancement by medium chain fatty acids in intestinal epithelial Caco-2 cell monolayers. The Journal of pharmacology and experimental therapeutics 275: 958–964.
[29]
Lindmark T, Soderholm JD, Olaison G, Alvan G, Ocklind G, et al. (1997) Mechanism of absorption enhancement in humans after rectal administration of ampicillin in suppositories containing sodium caprate. Pharmaceutical research 14: 930–935.
[30]
Tomita M, Hayashi M, Awazu S (1995) Absorption-enhancing mechanism of sodium caprate and decanoylcarnitine in Caco-2 cells. The Journal of pharmacology and experimental therapeutics 272: 739–743.
[31]
Tomita M, Hayashi M, Awazu S (1996) Absorption-enhancing mechanism of EDTA, caprate, and decanoylcarnitine in Caco-2 cells. Journal of pharmaceutical sciences 85: 608–611.
[32]
Andoh A, Bamba T, Sasaki M (1999) Physiological and anti-inflammatory roles of dietary fiber and butyrate in intestinal functions. JPEN Journal of parenteral and enteral nutrition 23: S70–73.
[33]
Venkatraman A, Ramakrishna BS, Pulimood AB, Patra S, Murthy S (2000) Increased permeability in dextran sulphate colitis in rats: time course of development and effect of butyrate. Scandinavian journal of gastroenterology 35: 1053–1059.
[34]
Venkatraman A, Ramakrishna BS, Shaji RV, Kumar NS, Pulimood A, et al. (2003) Amelioration of dextran sulfate colitis by butyrate: role of heat shock protein 70 and NF-kappaB. American journal of physiology Gastrointestinal and liver physiology 285: G177–184.
[35]
Vieira EL, Leonel AJ, Sad AP, Beltrao NR, Costa TF, et al. (2011) Oral administration of sodium butyrate attenuates inflammation and mucosal lesion in experimental acute ulcerative colitis. The Journal of nutritional biochemistry.
[36]
Charrier L, Yan Y, Driss A, Laboisse CL, Sitaraman SV, et al. (2005) ADAM-15 inhibits wound healing in human intestinal epithelial cell monolayers. Am J Physiol Gastrointest Liver Physiol 288: G346–353.
[37]
Laroui H, Grossin L, Leonard M, Stoltz JF, Gillet P, et al. (2007) Hyaluronate-covered nanoparticles for the therapeutic targeting of cartilage. Biomacromolecules 8: 3879–3885.
[38]
Lamprecht A, Yamamoto H, Takeuchi H, Kawashima Y (2005) A pH-sensitive microsphere system for the colon delivery of tacrolimus containing nanoparticles. J Control Release 104: 337–346.
[39]
Laroui H, Dalmasso G, Nguyen HT, Yan Y, Sitaraman SV, et al. (2010) Drug-loaded nanoparticles targeted to the colon with polysaccharide hydrogel reduce colitis in a mouse model. Gastroenterology 138: 843–853 e841–842.
[40]
Laroui H, Theiss AL, Yan Y, Dalmasso G, Nguyen HT, et al. (2011) Functional TNFalpha gene silencing mediated by polyethyleneimine/TNFalpha siRNA nanocomplexes in inflamed colon. Biomaterials 32: 1218–1228.
[41]
Vowinkel T, Kalogeris TJ, Mori M, Krieglstein CF, Granger DN (2004) Impact of dextran sulfate sodium load on the severity of inflammation in experimental colitis. Dig Dis Sci 49: 556–564.
[42]
Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, et al. (2011) Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells ameliorates acute murine colitis. Inflamm Bowel Dis 17: 1163–1176.
[43]
Shea-Donohue T, Thomas K, Cody MJ, Aiping Z, Detolla LJ, et al. (2008) Mice deficient in the CXCR2 ligand, CXCL1 (KC/GRO-alpha), exhibit increased susceptibility to dextran sodium sulfate (DSS)-induced colitis. Innate Immun 14: 117–124.
[44]
te Velde AA, de Kort F, Sterrenburg E, Pronk I, ten Kate FJ, et al. (2007) Comparative analysis of colonic gene expression of three experimental colitis models mimicking inflammatory bowel disease. Inflamm Bowel Dis 13: 325–330.
[45]
Mitsuyama K, Tsuruta O, Tomiyasu N, Takaki K, Suzuki A, et al. (2006) Increased circulating concentrations of growth-related oncogene (GRO)-alpha in patients with inflammatory bowel disease. Dig Dis Sci 51: 173–177.
[46]
Laroui H, Wilson DS, Dalmasso G, Salaita K, Murthy N, et al. (2011) Nanomedicine in GI. Am J Physiol Gastrointest Liver Physiol 300: G371–383.
[47]
Schmidt C, Dignass A, Hartmann F, Huppe D, Kruis W, et al. (2011) [IBD Ahead 2010 - Answering Important Questions in Crohn's Disease Treatment]. Zeitschrift fur Gastroenterologie 49: 1246–1254.
